We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+12.62%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$615M
AUM Growth
+$85.2M
Cap. Flow
+$34.9M
Cap. Flow %
5.67%
Top 10 Hldgs %
53.32%
Holding
366
New
100
Increased
78
Reduced
73
Closed
88

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$19.3M
2
ASND icon
Ascendis Pharma A/S
ASND
+$14.9M
3
ZURA icon
Zura Bio
ZURA
+$14.1M
4
AAM
AA Mission Acquisition Corp
AAM
+$10.1M
5
ZLAB icon
Zai Lab
ZLAB
+$9.65M

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$25.2M
2
ROIV icon
Roivant Sciences
ROIV
+$12.8M
3
MRK icon
Merck
MRK
+$8.86M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$8.32M
5
QURE icon
uniQure
QURE
+$5.48M

Sector Composition

Rank Sector Weight
1 Healthcare 85.92%
2 Financials 3.35%
3 Communication Services 0.57%
4 Technology 0.47%
5 Utilities 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VERU icon
226
Veru
VERU
$37.4M
$39.2K 0.01%
+5,100
New +$44K
LUMO
227
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$38.7K 0.01%
+10,000
New +$27.7K
PHVS icon
228
Pharvaris
PHVS
$2.44B
$37K 0.01%
2,000
– –
PYXS icon
229
Pyxis Oncology
PYXS
$236M
$36.7K 0.01%
10,000
– –
FBRX icon
230
Forte Biosciences
FBRX
$1.57B
$33.5K 0.01%
6,000
-370
-6% -$3.81K
AMLX icon
231
CALL
Amylyx Pharmaceuticals
AMLX
$2.54B
$32.4K 0.01%
10,000
– –
IDYA icon
232
IDEAYA Biosciences
IDYA
$3.56B
$31.7K 0.01%
1,000
+700
+233% +$26.5K
AAM.WS
233
DELISTED
AA Mission Acquisition Corp Warrants
AAM.WS
$30.3K ﹤0.01%
+505,099
New +$27K
BHC icon
234
Bausch Health
BHC
$2.34B
$30.2K ﹤0.01%
+3,700
New +$24.4K
NATL icon
235
NCR Atleos
NATL
$3.44B
$28.5K ﹤0.01%
1,000
– –
IONS icon
236
Ionis Pharmaceuticals
IONS
$9.4B
$28K ﹤0.01%
700
-800
-53% -$37.2K
RNAM
237
DELISTED
Avidity Biosciences
RNAM
$27.6K ﹤0.01%
+600
New +$26K
VYX icon
238
NCR Voyix
VYX
$1.14B
$27.1K ﹤0.01%
2,000
– –
PRGO icon
239
Perrigo
PRGO
$1.78B
$26.2K ﹤0.01%
1,000
-100
-9% -$2.75K
TGTX icon
240
PUT
TG Therapeutics
TGTX
$7.62B
$23.4K ﹤0.01%
+1,000
New +$21.8K
NGNE icon
241
Neurogene
NGNE
$712M
$23.2K ﹤0.01%
553
-700
-56% -$27.1K
GOSS icon
242
CALL
Gossamer Bio
GOSS
$87M
$19.7K ﹤0.01%
20,000
– –
KRYS icon
243
Krystal Biotech
KRYS
$9.66B
$18.2K ﹤0.01%
+100
New +$19.3K
KROS icon
244
CALL
Keros Therapeutics
KROS
$221M
$17.4K ﹤0.01%
+300
New +$14.8K
NTLA icon
245
Intellia Therapeutics
NTLA
$1.67B
$16.4K ﹤0.01%
+800
New +$18.4K
EYPT icon
246
EyePoint Inc
EYPT
$1.2B
$16K ﹤0.01%
+2,000
New +$17.6K
RLYB icon
247
Rallybio
RLYB
$85.8M
$15.6K ﹤0.01%
1,663
+263
+19% +$2.53K
RAPT
248
DELISTED
RAPT Therapeutics
RAPT
$15.1K ﹤0.01%
938
– –
DYN icon
249
Dyne Therapeutics
DYN
$4.9B
$14.4K ﹤0.01%
+400
New +$15.9K
ENGN icon
250
enGene Therapeutics
ENGN
$121M
$13K ﹤0.01%
1,970
+1,370
+228% +$10.2K
8 9
10
11 12

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, ADAR1 Capital Management held 366 positions worth $615M, up 16% from $530M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

ADAR1 Capital Management deployed $34.9M of net new capital in Q3 2024, opening 100 new positions and adding to 78 existing holdings. Its largest new stake was Zura Bio: 3,770,649 shares worth $15.3M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 80% a quarter earlier, followed by Financials and Communication Services.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $25.2M trimmed.

  • ADAR1 Capital Management's largest Q3 2024 buy was Zura Bio: 3,770,649 shares worth $15.3M.
  • ADAR1 Capital Management added most to Immunovant in Q3 2024, an estimated $19.3M increase.
  • ADAR1 Capital Management's biggest Q3 2024 reduction was Protagonist Therapeutics, cutting an estimated $25.2M.
  • ADAR1 Capital Management fully exited uniQure in Q3 2024, selling an estimated $5.48M.
  • ADAR1 Capital Management's ten largest holdings make up 53% of its $615M portfolio in Q3 2024.
  • ADAR1 Capital Management opened 100 new positions and closed 88 in Q3 2024.
  • ADAR1 Capital Management's portfolio value rose 16% quarter-over-quarter to $615M.

Based on ADAR1 Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.